Skip to main content
MANE logo

MANE · Veradermics, Inc · Metrics

Track MANE — free
$124.39 -0.47 (-0.38%) At close · Nov 19
Market Cap
$5.25B
Shares
42.20M
Volume · Nov 19 293.74K Avg daily vol (3M) 739.62K

MANE metrics

64 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$124.39
Market cap
$5.25B

Price action

23 metrics
Price change (1W)
-8.1%
Price change (30D)
-2.1%
Price change (3M)
+18.1%
Price change (6M)
+18.8%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
91.9%
Annualized volatility (3M)
72.5%
Implied volatility (30D)
57.5%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.2
RSI (14D)
44.9
Price vs SMA 50
+0.1%
Price vs SMA 200
+28.3%
Avg volume (3M)
739,617
Relative volume
0.4
Average dollar volume
$88.36M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
42.20M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
6.6
reciprocal yield 15.2%
FCF yield
-1.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-1.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-10-19

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$111.20M
Net income (TTM)
−$93.58M
Trailing 12 months
Diluted EPS (TTM)
$-40.18
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-33.42
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-31.42
Operating cash flow per diluted share (TTM)
$-33.35
Free cash flow per diluted share (TTM)
$-33.37
Capital expenditures per diluted share (TTM)
$0.02
R&D per diluted share (TTM)
$26.03
Stock compensation per diluted share (TTM)
$1.71
Book value per share
$-161.40

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+5,526.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-11.7%
Return on assets
-11.6%
Debt / equity
0.0
Current ratio
77.7
EBITDA (TTM)
—
Free cash flow (TTM)
−$82.60M
Quick ratio
77.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$132.16M
Latest balance sheet
Cash & equivalents
$132.16M
Total assets
$807.22M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$82.23M
Capital expenditures (TTM)
$372,000
R&D (TTM)
$73.80M
SG&A (TTM)
—
Stock compensation (TTM)
$13.84M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
208
13F filer change QoQ
+43
Institutional ownership
86.3%
Conviction holders (share of 13F filers)
2.9%
Crowding (high-turnover and private-fund holders)
41.2%
Private-fund adviser ownership
37.7%
Active holders' share change QoQ
+4.9%
Holder tenure
2.8
Price vs estimated holder cost
+63.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
5.4%

Short interest

3 metrics
Short interest
8.0%
Latest settlement · 5.1 days to cover
Days to cover
5.1d
Short-squeeze score
70 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$75.19M
Insider-sentiment score
15 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1827635 CUSIP 922967104 13F (30d) 201 filings 198 filers Visit website Investor relations